Endothelin-1: the body's most powerful blood-vessel-constricting hormone

What this is

Endothelin-1 (ET-1) is a 21-amino acid vasoactive peptide produced primarily by vascular endothelial cells and is the most potent endogenous vasoconstrictor known in mammalian physiology. It was isolated and sequenced from cultured bovine aortic endothelial cell supernatants by Yanagisawa and colleagues in 1988 (Nature), immediately establishing a new paradigm for vascular biology. ET-1 acts via two G-protein-coupled receptors — endothelin type A (ET-A) and endothelin type B (ET-B) — with opposing effects depending on receptor subtype and cell type: ET-A on vascular smooth muscle cells mediates potent, sustained vasoconstriction; ET-B on endothelial cells mediates vasodilation (through nitric oxide and prostacyclin release) and ET-1 clearance; ET-B on smooth muscle cells also mediates vasoconstriction. The stored sequence CSCSSLMDKECVYFCHLDIIW is the canonical 21-aa human form; the two disulfide bonds (Cys1–Cys15 and Cys3–Cys11) that form the bicyclic ring structure essential for receptor binding are not visible in the single-letter sequence.

ET-1 itself is not used as a pharmaceutical drug — it produces intense, sustained vasoconstriction and is not therapeutically administered. Its pharmacological importance lies in: (1) its role as a pathophysiological mediator in cardiovascular disease, pulmonary arterial hypertension (PAH), heart failure, renal disease, and sickle cell disease; and (2) as the target of the endothelin receptor antagonist (ERA) drug class, which includes bosentan (Tracleer, FDA-approved 2001), ambrisentan (Letairis, FDA-approved 2007), and macitentan (Opsumit, FDA-approved 2013) for pulmonary arterial hypertension. ET-1 is used in research as a pharmacological tool to induce vasoconstriction in isolated vessel preparations and to model vascular pathophysiology.

History

The existence of an endothelium-derived contracting factor (EDCF) was inferred from studies in the mid-1980s showing that endothelial cells, when mechanically stimulated or exposed to thrombin or hypoxia, released a potent vasoconstrictor substance into culture media. The breakthrough came in 1988 when Yanagisawa and colleagues at the University of Tsukuba isolated the active peptide from bovine aortic endothelial cell supernatants, determined its 21-aa sequence, cloned the precursor cDNA, and established that this peptide — named endothelin — was a more potent vasoconstrictor than any substance previously known, with an EC50 in the picomolar range in isolated vascular preparations (Yanagisawa et al. 1988).

The original 1988 Nature paper demonstrated that synthetic ET-1 induced long-lasting vasoconstriction of porcine coronary arteries at subnanomolar concentrations, and that the peptide was not displaced by endothelin-specific antiserum for hours after application — indicating an extremely tight receptor binding with slow dissociation. Subsequent cloning and characterization identified the full three-member endothelin family (ET-1, ET-2, ET-3) and their two cognate receptors (ET-A and ET-B), establishing the endothelin system as a major vasoregulatory axis.

The rapid recognition that ET-1 was markedly elevated in PAH, pulmonary hypertension associated with congenital heart disease, chronic heart failure, and acute MI directed pharmaceutical interest toward ET receptor antagonists. Bosentan, a non-selective ET-A/ET-B antagonist, received FDA approval in 2001 for PAH — the first ERA and first oral therapy for PAH approved in the US. Ambrisentan (selective ET-A antagonist) and macitentan (non-selective, tissue-penetrant ERA) followed. These drugs established ET-1 as one of the most therapeutically validated vasoactive peptide targets in cardiovascular medicine (Davenport et al. 2016).

What it does

ET-1 is synthesized from a 212-aa preproET-1 precursor through two proteolytic steps: furin-like proteases cleave preproET-1 to the 38-aa big ET-1; endothelin-converting enzyme-1 (ECE-1) then cleaves big ET-1 at the Trp21–Val22 bond to release mature 21-aa ET-1. ET-1 secretion is primarily abluminal (into the vessel wall) rather than luminal, reflecting its primary role as an autocrine/paracrine rather than endocrine signal. Circulating ET-1 levels are low in healthy adults and increase significantly in PAH, heart failure, and renal disease (Davenport et al. 2016).

ET-A receptor (vasoconstriction): ET-A is expressed predominantly on vascular smooth muscle cells (VSMCs). ET-1 binding activates Gαq → PLC → IP3 → intracellular Ca²⁺ release → MLCK activation → myosin light chain phosphorylation → sustained contraction. ET-A also activates PKC pathways that maintain prolonged vasoconstriction independent of Ca²⁺ elevation. The vasoconstriction is strikingly persistent — ET-1-induced contraction is among the longest-lasting of any known vasoactive substance, consistent with its tight receptor binding and slow dissociation kinetics.

ET-B receptor (dual effects): ET-B is expressed on both endothelial cells and VSMCs. On endothelial cells, ET-B stimulation triggers release of nitric oxide (eNOS activation) and prostacyclin (COX pathway), producing vasodilation — the counterregulatory endothelial ET-B response that limits ET-1-driven vasoconstriction. On VSMCs, ET-B mediates additional vasoconstriction. ET-B on pulmonary endothelium also serves as the primary clearance receptor for circulating ET-1, accounting for approximately 50% of systemic ET-1 removal. This means ET-B antagonism (non-selective ERAs like bosentan and macitentan) blocks both the vasodilatory/clearance functions and the vasoconstrictor function of ET-B (Davenport et al. 2016).

Pathophysiological roles: ET-1 is elevated in PAH (plasma and BAL fluid), where it drives pulmonary vasoconstriction, vascular smooth muscle hypertrophy, and endothelial dysfunction in a self-amplifying loop. In left ventricular failure, ET-1 causes pulmonary and systemic vasoconstriction, promotes cardiac fibrosis, and correlates with NYHA class and prognosis. In sickle cell disease, ET-1 contributes to vasoocclusive crisis. In renal disease, ET-1 mediates afferent arteriole vasoconstriction and mesangial cell contraction, contributing to proteinuria and progressive glomerulosclerosis (Davenport et al. 2016).

Evidence

• Human: Extensive clinical evidence via the ERA drug class. The ARIES-1 and ARIES-2 trials established ambrisentan's efficacy in PAH; the SERAPHIN trial (macitentan) demonstrated morbidity/mortality benefit in PAH. Bosentan's Phase III BREATHE-1 trial showed improved exercise capacity and delayed clinical worsening in WHO class III–IV PAH. Big ET-1 (38-aa precursor) is elevated in plasma in heart failure and correlates with cardiac functional class and outcomes (Davenport et al. 2016).
• Animal: ET-1 infusion in rodent and ovine models reproducibly induces pulmonary vasoconstriction, right ventricular hypertrophy, and vascular remodeling. ET-1 overexpression in transgenic mice produces systemic and pulmonary hypertension with end-organ injury. ECE-1 knockout models demonstrate the requirement of the processing step for mature ET-1 vasoactivity (Davenport et al. 2016).
• In vitro: Yanagisawa and colleagues (1988) demonstrated that synthetic ET-1 contracted porcine coronary artery ring preparations at concentrations far below those required for angiotensin II or norepinephrine to produce equivalent contraction, establishing ET-1 as the most potent vasoconstrictor peptide known. Radioligand binding studies have characterized ET-A selectivity (ET-1 = ET-2 > ET-3) and ET-B pan-selectivity (ET-1 = ET-2 = ET-3) (Davenport et al. 2016).

Myths and misconceptions

• "Endothelin receptor antagonists treat ET-1 excess" — ERAs are used in PAH not necessarily because ET-1 levels are dramatically elevated, but because the ET system's contribution to vasoconstriction and pulmonary vascular remodeling is disproportionately large in PAH. Many PAH patients have plasma ET-1 values only modestly above normal; the therapeutic effect of ERAs relates to tonic ET system activity in diseased pulmonary vasculature, not to correcting a massive ET-1 excess per se.
• "ET-1 causes only vasoconstriction" — ET-B receptors on endothelial cells mediate vasodilation via NO and prostacyclin — the so-called endothelin paradox. In healthy conduit arteries, ET-1 infusion at low doses can paradoxically vasodilate (endothelial ET-B → NO dominates); at higher doses, VSMC ET-A/ET-B-mediated constriction prevails. This dual receptor system makes ET-1's vascular effects highly context-dependent and explains why ET-B selectivity for antagonism vs. agonism produces different cardiovascular outcomes.
• "ET-1 is only a vascular peptide" — ET-1, ET-2, and ET-3 are expressed in brain (ET-B predominates), kidney (ET-1 in collecting duct; drives sodium retention via ET-B), lung (non-endothelial ET-1 in airway epithelium), gut, and gonads. The endothelin system participates in fluid balance regulation, neural development (ET-3/ET-B axis is essential for enteric nervous system and neural crest migration — loss of ET-3 or ET-B causes Hirschsprung disease-like phenotype in mice), and reproductive biology (Davenport et al. 2016).

Common questions

What is the structural basis for ET-1's potency and persistence of action? ET-1's two disulfide bonds (Cys1–Cys15 and Cys3–Cys11) create a constrained bicyclic ring structure that presents the C-terminal hydrophobic tail (LDIIW) in a defined conformation essential for receptor binding. The C-terminal Trp21 is indispensable — its removal abolishes biological activity. The unusually slow dissociation rate of ET-1 from ET-A and ET-B receptors accounts for the sustained vasoconstriction that outlasts peptide clearance from the receptor environment, a behavior unlike most other vasoactive peptides (Yanagisawa et al. 1988; Davenport et al. 2016).

Why do non-selective vs. ET-A selective ERAs have similar clinical outcomes in PAH? The theoretical advantage of ET-A selectivity (preserving ET-B-mediated endothelial vasodilation and ET-B-mediated plasma clearance of ET-1) has not translated into superior clinical outcomes in PAH trials. Several explanations have been proposed: in diseased PAH vessels, the endothelial ET-B vasodilatory response is already impaired, so preserving it confers little benefit; the VSMC ET-B constrictor contribution may offset the benefit of preserved endothelial ET-B; and ET-A/ET-B selectivities achieved by approved drugs are relative, not absolute, at therapeutic plasma concentrations. Head-to-head comparative PAH trials (AMBITION, SERAPHIN) have focused on background therapy combination and event-driven endpoints rather than receptor selectivity as an independent variable (Davenport et al. 2016).

Can ET-1 measurement be used clinically as a biomarker? Plasma ET-1 has a short half-life in circulation, largely due to ET-B-mediated pulmonary clearance. In practice, "big ET-1" (the 38-aa precursor, more stable in plasma) is measured as a surrogate and correlates with cardiac functional class, prognosis in heart failure, and disease severity in PAH. Big ET-1 is not a standard clinical test but is used in research and some specialized centers. Tissue ET-1 levels (from BAL fluid in PAH, from kidney biopsy in hypertensive nephropathy) better reflect local ET-1 activity than plasma levels (Davenport et al. 2016).

Mechanism

ET-1 is encoded by the EDN1 gene and processed from a 212-aa preproET-1 → 38-aa big ET-1 (by furin-like endopeptidases) → 21-aa mature ET-1 (by endothelin-converting enzyme-1, ECE-1, a membrane-bound metallopeptidase). The two-disulfide bicyclic structure (Cys1–Cys15 and Cys3–Cys11) is required for high-affinity receptor engagement. ET-A receptor binding (Kd in picomolar range, slow koff) activates Gαq/11 → PLCβ → IP3 → Ca²⁺ mobilization and DAG → PKC, sustaining vasoconstriction through both Ca²⁺-dependent and Ca²⁺-independent pathways. ET-B receptor signal transduction diverges by cell type: on endothelial cells, Gαi coupling inhibits adenylyl cyclase while Gαq drives eNOS phosphorylation and NO release; on VSMCs, ET-B also couples to Gαq for constriction. ET-A has selectivity for ET-1 and ET-2 over ET-3; ET-B binds all three isoforms with equal affinity (Davenport et al. 2016). Bosentan and macitentan are non-selective competitive antagonists at both ET-A and ET-B; ambrisentan is selective for ET-A. Approved ERA drugs are oral, making them the first orally bioavailable class for PAH.

Related peptides

• VIP (Vasoactive Intestinal Peptide) — endogenous vasoactive peptide with vasodilatory effects opposing ET-1; acts via VPAC receptors; studied in pulmonary vasodilation
• Secretin — gastrointestinal vasoactive hormone; vasodilatory via SCTR; context overlaps in gut-vascular biology
• BPC-157 — cytoprotective and angiogenic peptide discussed in vascular biology; no ET receptor connection